TRIM Family Proteins: Roles in Autophagy, Immunity, and Carcinogenesis

Trends in Biochemical Sciences

Volumn 42, Issue 4, 2017, Pages 297-311

  Hatakeyama, Shigetsugu ^a  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

autophagy; cancer; immunity; proteasome; TRIM; ubiquitin

Indexed keywords

DOUBLE STRANDED DNA; JANUS KINASE; PROTEASOME; STAT PROTEIN; TOLL LIKE RECEPTOR; TRIPARTITE MOTIF PROTEIN; UBIQUITIN; UBIQUITIN PROTEIN LIGASE E3;

APOPTOSIS; AUTOPHAGY; CARCINOGENESIS; CELL FUNCTION; CELL MATURATION; DEVELOPMENTAL DISORDER; ENZYME ACTIVATION; ENZYME ACTIVITY; HUMAN; IMMUNITY; IMMUNOPATHOLOGY; INNATE IMMUNITY; MALIGNANT NEOPLASM; NONHUMAN; PROTEIN DEGRADATION; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; PROTEIN QUALITY CONTROL; PROTEIN STRUCTURE; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; METABOLISM;

AUTOPHAGY; CARCINOGENESIS; HUMANS; IMMUNITY; TRIPARTITE MOTIF PROTEINS;

EID: 85009986021     PISSN: 09680004     EISSN: 13624326     Source Type: Journal    
DOI: 10.1016/j.tibs.2017.01.002     Document Type: Review

References (96)

1. 1 Hershko, A., Ciechanover, A., The ubiquitin system. Annu. Rev. Biochem. 67 (1998), 425–479.
2. 2 Huibregtse, J.M., et al. A family of proteins structurally and functionally related to the E6-AP ubiquitin–protein ligase. Proc. Natl. Acad. Sci. U. S. A. 92 (1995), 2563–2567.
3. 3 Freemont, P.S., RING for destruction?. Curr. Biol. 10 (2000), R84–R87.
4. 4 Joazeiro, C.A., Weissman, A.M., RING finger proteins: mediators of ubiquitin ligase activity. Cell 102 (2000), 549–552.
5. 5 Lorick, K.L., et al. RING fingers mediate ubiquitin-conjugating enzyme (E2)-dependent ubiquitination. Proc. Natl. Acad. Sci. U. S. A. 96 (1999), 11364–11369.
6. 6 Aravind, L., Koonin, E.V., The U box is a modified RING finger – a common domain in ubiquitination. Curr. Biol. 10 (2000), R132–R134.
7. 7 Cyr, D.M., et al. Protein quality control: U-box-containing E3 ubiquitin ligases join the fold. Trends Biochem. Sci. 27 (2002), 368–375.
8. 8 Hatakeyama, S., et al. U box proteins as a new family of ubiquitin–protein ligases. J. Biol. Chem. 276 (2001), 33111–33120.
9. 9 Wertz, I.E., et al. De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-κB signalling. Nature 430 (2004), 694–699.
10. 10 Rohde, J.R., et al. Type III secretion effectors of the IpaH family are E3 ubiquitin ligases. Cell Host Microbe 1 (2007), 77–83.
11. 11 Qiu, J., et al. Ubiquitination independent of E1 and E2 enzymes by bacterial effectors. Nature 533 (2016), 120–124.
12. 12 Sasaki, K., Iwai, K., Roles of linear ubiquitinylation, a crucial regulator of NF-κB and cell death, in the immune system. Immunol. Rev. 266 (2015), 175–189.
13. 13 Hatakeyama, S., TRIM proteins and cancer. Nat. Rev. Cancer 11 (2011), 792–804.
14. 14 Napolitano, L.M., Meroni, G., TRIM family: pleiotropy and diversification through homomultimer and heteromultimer formation. IUBMB Life 64 (2012), 64–71.
15. 15 Reymond, A., et al. The tripartite motif family identifies cell compartments. EMBO J. 20 (2001), 2140–2151.
16. 16 Short, K.M., Cox, T.C., Subclassification of the RBCC/TRIM superfamily reveals a novel motif necessary for microtubule binding. J. Biol. Chem. 281 (2006), 8970–8980.
17. 17 Ozato, K., et al. TRIM family proteins and their emerging roles in innate immunity. Nat. Rev. Immunol. 8 (2008), 849–860.
18. 18 McNab, F.W., et al. Tripartite-motif proteins and innate immune regulation. Curr. Opin. Immunol. 23 (2011), 46–56.
19. 19 Herquel, B., et al. Transcription cofactors TRIM24, TRIM28, and TRIM33 associate to form regulatory complexes that suppress murine hepatocellular carcinoma. Proc. Natl. Acad. Sci. U. S. A. 108 (2011), 8212–8217.
20. 20 Stevenson, M., TRIMming HIV-1’s mainsail. Nat. Immunol. 5 (2004), 355–356.
21. 21 Keown, J.R., et al. Characterisation of assembly and ubiquitylation by the RBCC motif of Trim5α. Sci. Rep., 6, 2016, 26837.
22. 22 Weinert, C., et al. Crystal structure of TRIM20 C-terminal coiled-coil/B30.2 fragment: implications for the recognition of higher order oligomers. Sci. Rep., 5, 2015, 10819.
23. 23 Mizushima, N., Komatsu, M., Autophagy: renovation of cells and tissues. Cell 147 (2011), 728–741.
24. 24 Komatsu, M., et al. Homeostatic levels of p62 control cytoplasmic inclusion body formation in autophagy-deficient mice. Cell 131 (2007), 1149–1163.
25. 25 Deretic, V., Autophagy as an innate immunity paradigm: expanding the scope and repertoire of pattern recognition receptors. Curr. Opin. Immunol. 24 (2012), 21–31.
26. 26 Lange, S., et al. The kinase domain of titin controls muscle gene expression and protein turnover. Science 308 (2005), 1599–1603.
27. 27 Perera, S., et al. Developmental regulation of MURF ubiquitin ligases and autophagy proteins nbr1, p62/SQSTM1 and LC3 during cardiac myofibril assembly and turnover. Dev. Biol. 351 (2011), 46–61.
28. 28 Pizon, V., et al. MURF2B, a novel LC3-binding protein, participates with MURF2A in the switch between autophagy and ubiquitin proteasome system during differentiation of C2C12 muscle cells. PLoS One, 8, 2013, e76140.
29. 29 Khan, M.M., et al. Role of autophagy, SQSTM1, SH3GLB1, and TRIM63 in the turnover of nicotinic acetylcholine receptors. Autophagy 10 (2014), 123–136.
30. 30 Niida, M., et al. Downregulation of active IKK beta by Ro52-mediated autophagy. Mol. Immunol. 47 (2010), 2378–2387.
31. 31 Tomar, D., et al. TRIM13 regulates ER stress induced autophagy and clonogenic ability of the cells. Biochim. Biophys. Acta 1823 (2012), 316–326.
32. 32 Barde, I., et al. A KRAB/KAP1–miRNA cascade regulates erythropoiesis through stage-specific control of mitophagy. Science 340 (2013), 350–353.
33. 33 Yang, Y., et al. Acetylated hsp70 and KAP1-mediated Vps34 SUMOylation is required for autophagosome creation in autophagy. Proc. Natl Acad. Sci. U. S. A. 110 (2013), 6841–6846.
34. 34 Mandell, M.A., et al. TRIM proteins regulate autophagy and can target autophagic substrates by direct recognition. Dev. Cell 30 (2014), 394–409.
35. 35 Kimura, T., et al. Precision autophagy directed by receptor regulators – emerging examples within the TRIM family. J. Cell Sci. 129 (2016), 881–891.
36. 36 Kimura, T., et al. TRIM-mediated precision autophagy targets cytoplasmic regulators of innate immunity. J. Cell Biol. 210 (2015), 973–989.
37. 37 Heaton, S.M., et al. Ubiquitin in the activation and attenuation of innate antiviral immunity. J. Exp. Med. 213 (2016), 1–13.
38. 38 Grutter, M.G., Luban, J., TRIM5 structure, HIV-1 capsid recognition, and innate immune signaling. Curr. Opin. Virol. 2 (2012), 142–150.
39. 39 Gack, M.U., et al. Influenza A virus NS1 targets the ubiquitin ligase TRIM25 to evade recognition by the host viral RNA sensor RIG-I. Cell Host Microbe 5 (2009), 439–449.
40. 40 Rajsbaum, R., et al. Species-specific inhibition of RIG-I ubiquitination and IFN induction by the influenza A virus NS1 protein. PLoS Pathog., 8, 2012, e1003059.
41. 41 Laurent-Rolle, M., The interferon signaling antagonist function of yellow fever virus NS5 protein is activated by type I interferon. Cell Host Microbe 16 (2014), 314–327.
42. 42 Rajsbaum, R., Garcia-Sastre, A., Viral evasion mechanisms of early antiviral responses involving regulation of ubiquitin pathways. Trends Microbiol. 21 (2013), 421–429.
43. 43 Versteeg, G.A., et al. InTRIMsic immunity: positive and negative regulation of immune signaling by tripartite motif proteins. Cytokine Growth Factor Rev. 25 (2014), 563–576.
44. 44 Rajsbaum, R., et al. Unanchored K48-linked polyubiquitin synthesized by the E3-ubiquitin ligase TRIM6 stimulates the interferon–IKKε kinase-mediated antiviral response. Immunity 40 (2014), 880–895.
45. 45 Bharaj, P., et al. The Matrix Protein of Nipah Virus Targets the E3-Ubiquitin Ligase TRIM6 to Inhibit the IKKε Kinase-Mediated Type-I IFN Antiviral Response. PLoS Pathog, 12, 2016, e1005880.
46. 46 Toniato, E., et al. TRIM8/GERP RING finger protein interacts with SOCS-1. J. Biol. Chem. 277 (2002), 37315–37322.
47. 47 Okumura, F., et al. TRIM8 modulates STAT3 activity through negative regulation of PIAS3. J. Cell Sci. 123 (2010), 2238–2245.
48. 48 Pertel, T., et al. TRIM5 is an innate immune sensor for the retrovirus capsid lattice. Nature 472 (2011), 361–365.
49. 49 Zhao, W., et al. E3 ubiquitin ligase tripartite motif 38 negatively regulates TLR-mediated immune responses by proteasomal degradation of TNF receptor-associated factor 6 in macrophages. J. Immunol. 188 (2012), 2567–2574.
50. 50 Hu, M.M., et al. TRIM38 inhibits TNFα- and IL-1β-triggered NF-κB activation by mediating lysosome-dependent degradation of TAB2/3. Proc. Natl. Acad. Sci. U. S. A. 111 (2014), 1509–1514.
51. 51 Hu, M.M., et al. TRIM38 negatively regulates TLR3/4-mediated innate immune and inflammatory responses by two sequential and distinct mechanisms. J. Immunol. 195 (2015), 4415–4425.
52. 52 Poole, E., et al. Identification of TRIM23 as a cofactor involved in the regulation of NF-κB by human cytomegalovirus. J. Virol. 83 (2009), 3581–3590.
53. 53 Uchil, P.D., et al. TRIM protein-mediated regulation of inflammatory and innate immune signaling and its association with antiretroviral activity. J. Virol. 87 (2013), 257–272.
54. 54 Qiu, H., et al. TRIM22 inhibits the TRAF6-stimulated NF-κB pathway by targeting TAB2 for degradation. Virol. Sin. 28 (2013), 209–215.
55. 55 Li, Q., et al. Tripartite motif 8 (TRIM8) modulates TNFα- and IL-1β-triggered NF-κB activation by targeting TAK1 for K63-linked polyubiquitination. Proc. Natl Acad. Sci. U. S. A. 108 (2011), 19341–19346.
56. 56 Shi, M., et al. TRIM30α negatively regulates TLR-mediated NF-κB activation by targeting TAB2 and TAB3 for degradation. Nat. Immunol. 9 (2008), 369–377.
57. 57 Arimoto, K., et al. Polyubiquitin conjugation to NEMO by triparite motif protein 23 (TRIM23) is critical in antiviral defense. Proc. Natl Acad. Sci. U. S. A. 107 (2010), 15856–15861.
58. 58 Zha, J., et al. The Ret finger protein inhibits signaling mediated by the noncanonical and canonical IκB kinase family members. J. Immunol. 176 (2006), 1072–1080.
59. 59 Noguchi, K., et al. TRIM40 promotes neddylation of IKKγ and is downregulated in gastrointestinal cancers. Carcinogenesis 32 (2011), 995–1004.
60. 60 Shi, M., et al. Negative regulation of NF-κB activity by brain-specific TRIpartite motif protein 9. Nat. Commun., 5, 2014, 4820.
61. 61 Chae, J.J., et al. The familial Mediterranean fever protein, pyrin, is cleaved by caspase-1 and activates NF-κB through its N-terminal fragment. Blood 112 (2008), 1794–1803.
62. 62 Tomar, D., et al. Nucleo-cytoplasmic trafficking of TRIM8, a novel oncogene, is involved in positive regulation of TNF induced NF-κB pathway. PLoS One, 7, 2012, e48662.
63. 63 Wu, W.S., et al. Promyelocytic leukemia protein sensitizes tumor necrosis factor alpha-induced apoptosis by inhibiting the NF-κB survival pathway. J. Biol. Chem. 278 (2003), 12294–12304.
64. 64 Suzuki, M., et al. TRIM39 negatively regulates the NFκB-mediated signaling pathway through stabilization of Cactin. Cell. Mol. Life Sci. 73 (2016), 1085–1101.
65. 65 Shibata, M., et al. TRIM45 negatively regulates NF-κB-mediated transcription and suppresses cell proliferation. Biochem. Biophys. Res. Commun. 423 (2012), 104–109.
66. 66 Shen, Y., et al. TRIM56 is an essential component of the TLR3 antiviral signaling pathway. J. Biol. Chem. 287 (2012), 36404–36413.
67. 67 Zhang, Z., et al. The E3 ubiquitin ligase TRIM21 negatively regulates the innate immune response to intracellular double-stranded DNA. Nat. Immunol. 14 (2013), 172–178.
68. 68 Tsuchida, T., et al. The ubiquitin ligase TRIM56 regulates innate immune responses to intracellular double-stranded DNA. Immunity 33 (2010), 765–776.
69. 69 Narayan, K., et al. TRIM13 is a negative regulator of MDA5-mediated type I interferon production. J. Viro. 88 (2014), 10748–10757.
70. 70 Zhou, Z., et al. TRIM14 is a mitochondrial adaptor that facilitates retinoic acid-inducible gene-I-like receptor-mediated innate immune response. Proc. Natl Acad. Sci. U. S. A. 111 (2014), E245–E254.
71. 71 Yang, B., et al. Novel function of Trim44 promotes an antiviral response by stabilizing VISA. J. Immunol. 190 (2013), 3613–3619.
72. 72 Kondo, T., et al. TRIM59 interacts with ECSIT and negatively regulates NF-κB and IRF-3/7-mediated signal pathways. Biochem. Biophys. Res. Commun. 422 (2012), 501–507.
73. 73 Lee, Y., et al. TRIM11 negatively regulates IFNβ production and antiviral activity by targeting TBK1. PLoS One, 8, 2013, e63255.
74. 74 Zhao, W., et al. Tripartite motif-containing protein 38 negatively regulates TLR3/4- and RIG-I-mediated IFN-β production and antiviral response by targeting NAP1. J. Immunol. 188 (2012), 5311–5318.
75. 75 Wynne, C., et al. TRIM68 negatively regulates IFN-β production by degrading TRK fused gene, a novel driver of IFN-β downstream of anti-viral detection systems. PLoS One, 9, 2014, e101503.
76. 76 Higgs, R., et al. The E3 ubiquitin ligase Ro52 negatively regulates IFN-β production post-pathogen recognition by polyubiquitin-mediated degradation of IRF3. J. Immunol. 181 (2008), 1780–1786.
77. 77 Lazzari, E., et al. TRIpartite motif 21 (TRIM21) differentially regulates the stability of interferon regulatory factor 5 (IRF5) isoforms. PLoS One, 9, 2014, e103609.
78. 78 Liang, Q., et al. Tripartite motif-containing protein 28 is a small ubiquitin-related modifier E3 ligase and negative regulator of IFN regulatory factor 7. J. Immunol. 187 (2011), 4754–4763.
79. 79 Versteeg, G.A., et al. The E3-ligase TRIM family of proteins regulates signaling pathways triggered by innate immune pattern-recognition receptors. Immunity 38 (2013), 384–398.
80. 80 White, E., The role for autophagy in cancer. J. Clin. Invest. 125 (2015), 42–46.
81. 81 Acres, B., et al. Therapeutic cancer vaccines. Curr. Opin. Mol. Ther. 6 (2004), 40–47.
82. 82 Cambiaghi, V., et al. TRIM proteins in cancer. Adv. Exp. Med. Biol. 770 (2012), 77–91.
83. 83 Allton, K., et al. Trim24 targets endogenous p53 for degradation. Proc. Natl Acad. Sci. U. S. A. 106 (2009), 11612–11616.
84. 84 Le Douarin, B., et al. The N-terminal part of TIF1, a putative mediator of the ligand-dependent activation function (AF-2) of nuclear receptors, is fused to B-raf in the oncogenic protein T18. EMBO J. 14 (1995), 2020–2033.
85. 85 Khetchoumian, K., et al. Loss of Trim24 (Tif1α) gene function confers oncogenic activity to retinoic acid receptor alpha. Nat. Genet. 39 (2007), 1500–1506.
86. 86 Kikuchi, M., et al. TRIM24 mediates ligand-dependent activation of androgen receptor and is repressed by a bromodomain-containing protein, BRD7, in prostate cancer cells. Biochim. Biophys. Acta 1793 (2009), 1828–1836.
87. 87 Groner, A.C., et al. TRIM24 is an oncogenic transcriptional activator in prostate cancer. Cancer Cell 29 (2016), 846–858.
88. 88 Yang, B., et al. MAGE-A, mMage-b, and MAGE-C proteins form complexes with KAP1 and suppress p53-dependent apoptosis in MAGE-positive cell lines. Cancer Res. 67 (2007), 9954–9962.
89. 89 Pineda, C.T., Potts, P.R., Oncogenic MAGEA–TRIM28 ubiquitin ligase downregulates autophagy by ubiquitinating and degrading AMPK in cancer. Autophagy 11 (2015), 844–846.
90. 90 Pineda, C.T., et al. Degradation of AMPK by a cancer-specific ubiquitin ligase. Cell 160 (2015), 715–728.
91. 91 Kanno, Y., et al. TRIM29 as a novel prostate basal cell marker for diagnosis of prostate cancer. Acta Histochem. 116 (2014), 708–712.
92. 92 Yuan, Z., et al. The ATDC (TRIM29) protein binds p53 and antagonizes p53-mediated functions. Mol. Cell. Biol. 30 (2010), 3004–3015.
93. 93 Yang, H., et al. ATDC (ataxia telangiectasia group D complementing) promotes radioresistance through an interaction with the RNF8 ubiquitin ligase. J. Biol. Chem. 290 (2015), 27146–27157.
94. 94 Masuda, Y., et al. TRIM29 regulates the assembly of DNA repair proteins into damaged chromatin. Nat. Commun., 6, 2015, 7299.
95. 95 Ai, L., et al. TRIM29 suppresses TWIST1 and invasive breast cancer behavior. Cancer Res. 74 (2014), 4875–4887.
96. 96 Kimura, T., et al. Dedicated SNAREs and specialized TRIM cargo receptors mediate secretory autophagy. EMBO J 36 (2017), 42–60.